Guggenheim Starts Aclaris Therapeutis (ACRS) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ACRS Hot Sheet
Price: $3.68 -1.6%
Rating Summary:
15 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
15 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutis (NASDAQ: ACRS) with a Buy rating and a price target of $12.00.
For an analyst ratings summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.
Shares of Aclaris Therapeutis closed at $4.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chardan Starts Vicore Pharma Holding (VCRE) at Buy
- Barclays Downgrades Michelin (ML:FP) (MGDDY) to Underweight
- Mahanagar Gas Limited (MAHGL:IN) PT Lowered to INR1,355 at Nomura/Instinet
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Guggenheim, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
